Doripenem

Doripenem
Clinical data
Trade names	Finibax, Doribax
AHFS/Drugs.com	Monograph
MedlinePlus	a608015
License data	EU EMA: by INN; US FDA: Doripenem;
Pregnancy; category	B;
Routes of; administration	IM, IV
ATC code	J01DH04 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Metabolism	Renal
Identifiers
	IUPAC name (4R,5S,6S)-6-(1-Hydroxyethyl)-4-methyl-7-oxo-3-(((5S)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;
CAS Number	148016-81-3 ;
PubChem CID	73303;
ChemSpider	66040 ;
UNII	BHV525JOBH;
KEGG	D03895 ;
ChEMBL	ChEMBL491571 ;
CompTox Dashboard (EPA)	DTXSID2046678 ;
Chemical and physical data
Formula	C15H24N4O6S2
Molar mass	420.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N)NC[C@H]3NC[C@@H](S\C2=C(\N1C(=O)[C@H]([C@H](O)C)[C@H]1[C@H]2C)C(=O)O)C3;
	InChI InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1 ; Key:AVAACINZEOAHHE-VFZPANTDSA-N ;
	(what is this?) (verify)

Doripenem (Doribax, Finibax) is an antibiotic drug in the carbapenem class. It is a beta-lactam antibiotic drug able to kill Pseudomonas aeruginosa.

Doripenem can be used for bacterial infections such as: complex abdominal infections, pneumonia within the setting of a hospital, and complicated infections of the urinary tract including kidney infections with sepsis.

The greater stability of doripenem in aqueous solution compared to earlier members of the carbapenem class allows it to be administered as an infusion over 4 hours or more, which may be advantageous in the treatment of certain difficult-to-treat infections.^[1]^[2] It may present a lower risk of inducing seizures than other carbapenems.^[3]

^ Mazzei T (August 2010). "The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem". Journal of Chemotherapy. 22 (4): 219–25. doi:10.1179/joc.2010.22.4.219. PMID 20685624. S2CID 72019292.
^ Greer ND (July 2008). "Doripenem (Doribax): the newest addition to the carbapenems". Proceedings. 21 (3): 337–41. doi:10.1080/08998280.2008.11928422. PMC 2446428. PMID 18628935.
^ Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R (2009). "Overview of seizure-inducing potential of doripenem". Drug Safety. 32 (9): 709–16. doi:10.2165/00002018-200932090-00001. PMID 19670912. S2CID 25385572.

[1] Mazzei T (August 2010). "The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem". Journal of Chemotherapy. 22 (4): 219–25. doi:10.1179/joc.2010.22.4.219. PMID 20685624. S2CID 72019292.

[2] Greer ND (July 2008). "Doripenem (Doribax): the newest addition to the carbapenems". Proceedings. 21 (3): 337–41. doi:10.1080/08998280.2008.11928422. PMC 2446428. PMID 18628935.

[3] Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R (2009). "Overview of seizure-inducing potential of doripenem". Drug Safety. 32 (9): 709–16. doi:10.2165/00002018-200932090-00001. PMID 19670912. S2CID 25385572.

[1]

[2]

[3]